Employees who take an over the counter allergy medication before a scheduled drug screen sometimes ask whether it could flag the test. The honest answer depends on which product is involved. Plain Claritin (loratadine) is a second generation antihistamine that is not a controlled substance and is not a target analyte on any standard workplace drug testing panel. Claritin D is a different product. It pairs loratadine with pseudoephedrine, a decongestant with documented presumptive cross reactivity on some amphetamine and methamphetamine immunoassays. This post walks through what the screening science actually shows, how confirmation testing sorts a true positive from a cross reactive result, and what the medical review officer process needs from the employee.
Loratadine alone: limited evidence of cross reactivity
Loratadine works on histamine H1 receptors and has no pharmacological relationship to amphetamines, opioids, cannabinoids, benzodiazepines, or any other drug class on a standard five or ten panel immunoassay. The FDA prescribing and OTC labeling for loratadine, published through the National Library of Medicine, does not list drug screen interference as a known effect, and no cross reactivity data for loratadine against amphetamine class immunoassays is published in the label. Where published evidence on a specific cross reactivity claim is thin or absent, the honest framing is that the evidence is limited rather than that a false positive is impossible or certain. For loratadine, that is exactly where things stand: limited to no documented cross reactivity on standard screens. See the DailyMed label for Claritin (loratadine) tablets for the full prescribing and OTC information on file with the National Library of Medicine.
Claritin D is the product that matters here
Claritin D 12 Hour and Claritin D 24 Hour combine loratadine with pseudoephedrine sulfate, a sympathomimetic amine sold as a nasal decongestant. Pseudoephedrine is chemically related to amphetamine and methamphetamine, and it is one of the better documented sources of a presumptive positive on amphetamine and methamphetamine screening immunoassays. The active ingredient and dosage amount are listed on the FDA regulated Drug Facts panel for the product. See the DailyMed label for Claritin D 24 Hour (loratadine and pseudoephedrine sulfate). Pseudoephedrine sulfate and pseudoephedrine hydrochloride are both recognized active ingredients under the FDA final monograph for over the counter nasal decongestant drug products, which sets the labeling and safety conditions these ingredients must meet; see the Federal Register final rule amending the OTC nasal decongestant monograph for the regulatory text covering pseudoephedrine containing products.
A peer reviewed retrospective study of urine drug screening results at a tertiary hospital, published through the National Institutes of Health PubMed Central archive, states plainly that the amphetamine immunoassay may react with over the counter decongestants such as pseudoephedrine, and that definitive testing by chromatographic mass spectrometric methods is preferable whenever the result carries real consequences. Read the discussion in this NIH PMC retrospective study on urine drug screening positivity and immunoassay cross reactivity.
Screening immunoassay vs confirmation testing
A workplace drug test is almost never a single step. The initial screen, whether run on a cup, a dip card, or an oral fluid device, uses an immunoassay that reacts to a class of structurally similar molecules, not to one specific drug. That is efficient and inexpensive, but it is also why cross reactivity happens at all. A nonnegative screen on a federally regulated test is never reported as a final result. It goes to a certified laboratory for confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC MS/MS), methods that identify the exact molecule present rather than a class of molecules. Pseudoephedrine and amphetamine have different molecular structures and different retention and mass signatures, so confirmation testing separates a pseudoephedrine driven screen result from an actual amphetamine or methamphetamine finding.
The cutoff concentrations used for federal workplace amphetamine and methamphetamine testing come from the HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs, published in the Federal Register. The current guidelines set an initial immunoassay cutoff of 500 ng/mL for the amphetamine/methamphetamine group, with confirmatory cutoffs of 250 ng/mL for amphetamine and 250 ng/mL for methamphetamine individually. See the Mandatory Guidelines for Federal Workplace Drug Testing Programs in the Federal Register for the full cutoff tables and confirmation criteria.
| Step | What it measures | Typical cutoff (federal urine programs) | What it can tell you |
|---|---|---|---|
| Initial immunoassay screen | Class level reaction to amphetamine type molecules | 500 ng/mL for the amphetamine/methamphetamine group | Presumptive only; cannot distinguish pseudoephedrine from amphetamine or methamphetamine |
| Confirmation (GC/MS or LC MS/MS) | Specific molecule identification | 250 ng/mL amphetamine, 250 ng/mL methamphetamine | Identifies the exact substance present, which separates a decongestant reaction from a true positive |
| Medical review officer (MRO) review | Clinical and documentation review of any nonnegative confirmed result | Not a lab step | Considers prescriptions, OTC use, and medical explanations before a result is reported to the employer |
What the MRO asks for
If a confirmed amphetamine or methamphetamine result comes back, a certified medical review officer contacts the donor before anything is reported to the employer. The MRO asks what medications were taken, when, and in what amount, and may ask for proof such as a pharmacy receipt, the product box, or a prescription label. This is the step where an employee who took Claritin D for a cold or seasonal allergies can explain the use. It is also why documentation matters more than memory. An employee who cannot produce any record of what they took has a harder conversation than one who kept the box or the receipt.
This process mirrors how other common stimulant adjacent medications get reviewed. For a closer look at how amphetamine confirmed results move through MRO review generally, see our related post on Adderall and amphetamine drug test MRO review. For the mechanism behind pseudoephedrine specific methamphetamine screen reactions, see pseudoephedrine and meth false positives.
What to keep on hand before a test
- Keep the original Claritin D box or blister pack, or a photo of it, until the testing window has passed.
- Keep the pharmacy or store receipt showing the purchase date.
- If loratadine or any other medication was prescribed rather than purchased over the counter, keep the prescription label or a pharmacy printout.
- Tell the collector or the MRO about recent OTC decongestant use at the time of collection if asked, rather than waiting until after a nonnegative result comes back.
What this does not mean for employers
None of this means an amphetamine confirmed result should be dismissed as routine. State law and company policy on how a confirmed, MRO reviewed result is handled vary, and employers should rely on their MRO's clinical determination and their own counsel rather than assuming any single explanation applies. Employers generally may rely on the laboratory's confirmed, MRO verified result for employment decisions, but the appropriate response to a verified positive is a policy and legal question that sits outside what a testing vendor can advise on.
Frequently asked questions
Does plain Claritin show up on a drug test?
Loratadine is not a target of any standard immunoassay panel and is not a controlled substance. Published evidence of cross reactivity with amphetamine, opioid, or other standard panels is limited to none, based on the current FDA labeling on file with DailyMed.
Does Claritin D show up as amphetamine on a drug test?
The pseudoephedrine in Claritin D can produce a presumptive positive on some amphetamine and methamphetamine immunoassay screens. Confirmation testing by GC/MS or LC MS/MS at the lab distinguishes pseudoephedrine from amphetamine and methamphetamine.
If a screen comes back nonnegative after taking Claritin D, is the job at risk?
A nonnegative screen is not a final result. It goes to confirmation testing, and any confirmed nonnegative result goes to a medical review officer, who contacts the donor about medications before anything is reported to the employer.
What should an employee tell the MRO about Claritin D use?
The dates and amount taken, and whether it was purchased over the counter or prescribed. Keeping the box, blister pack, or purchase receipt makes that conversation faster and better documented.
Can a lab tell the difference between pseudoephedrine and methamphetamine?
Yes. Confirmation methods identify the specific molecule present, which is why a federally regulated test never reports an immunoassay screen result as final without confirmation.
Is a drug test ever reported from the screen alone?
In federally regulated and most clinical laboratory based workplace programs, no. A nonnegative initial screen is confirmed by mass spectrometry before any result is sent to an MRO or reported to an employer.
Testing programs that account for common OTC interferences
Any workplace drug testing program should pair an initial screen with laboratory confirmation and MRO review rather than treating a screen alone as a final answer. American Screening Corporation supplies drug test cups, dip cards, and oral fluid devices built for exactly that two step process. Browse the drug test cup collection to see panel configurations available for employer and clinical screening programs.
This article is general information about drug testing science and process, not legal or medical advice. Testing policies, state law, and MRO procedures vary; consult qualified counsel or a certified medical review officer for guidance specific to any individual case.
